Testing effectiveness (Phase 2)Looking for participantsNCT05442515
What this trial is testing
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Who this might be right for
B-NHLB-Non Hodgkin LymphomaAcute Lymphocytic Leukemia+8 more
National Cancer Institute (NCI) 130